{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:55:26Z","timestamp":1781704526537,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jinf.2026.106710","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:13:18Z","timestamp":1771459998000},"page":"106710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of amikacin in patients with a haematological disorder: A prospective, observational study"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-7404","authenticated-orcid":false,"given":"Sarah","family":"Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sereina Livia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Bausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-1929","authenticated-orcid":false,"given":"Maja","family":"Weisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Rentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-638X","authenticated-orcid":false,"given":"Sebastiaan D.T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-1425","authenticated-orcid":false,"given":"Stefano","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6254-5207","authenticated-orcid":false,"given":"Verena","family":"Gotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-957X","authenticated-orcid":false,"given":"Michael","family":"Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jinf.2026.106710_bib1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2026.106710_bib2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2165\/00003495-199447060-00004","article-title":"Parenteral aminoglycoside therapy. Selection, administration and monitoring","volume":"47","author":"Kumana","year":"1994","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib3","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1111\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52 1","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jinf.2026.106710_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jinf.2026.106710_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.medmal.2011.07.007","article-title":"Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring","volume":"42","author":"Agence francaise de securite sanitaire des produits de s","year":"2012","journal-title":"Med Mal Infect"},{"issue":"6","key":"10.1016\/j.jinf.2026.106710_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jinf.2026.106710_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2017.09.019","article-title":"Impact of amikacin pharmacokinetic\/pharmacodynamic index on treatment response in critically ill patients","volume":"12","author":"Ruiz","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"10.1016\/j.jinf.2026.106710_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003088-200342050-00007","article-title":"Aminoglycoside dosages and nephrotoxicity: quantitative relationships","volume":"42","author":"Rougier","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.jinf.2026.106710_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1592\/phco.19.16.1252.30876","article-title":"Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside","volume":"19","author":"Murry","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2026.106710_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-020-00685-5","article-title":"Amikacin pharmacokinetic\/pharmacodynamic in intensive care unit: a prospective database","volume":"10","author":"Logre","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.jinf.2026.106710_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkg403","article-title":"Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis","volume":"52","author":"Zelenitsky","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jinf.2026.106710_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/j.1552-4604.1991.tb03700.x","article-title":"Amikacin pharmacokinetics: wide interpatient variation in 98 patients","volume":"31","author":"Zaske","year":"1991","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jinf.2026.106710_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J Pharm Pract"},{"issue":"7","key":"10.1016\/j.jinf.2026.106710_bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jinf.2026.106710_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"de Montmollin","year":"2014","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.jinf.2026.106710_bib18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/ppul.24689","article-title":"Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model","volume":"55","author":"Thirion","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jinf.2026.106710_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/antibiotics10020100","article-title":"Population pharmacokinetics analysis of amikacin initial dosing regimen in elderly patients","volume":"10","author":"Kato","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jinf.2026.106710_bib20","unstructured":"Guide S. BMI, BSA, IBW, LBW Calculator 2024 [cited 2024 04th October 2024]. Available from: \u3008https:\/\/web.sanfordguide.com\/en\/comparisons-1\/calculators\/sg-one-calculators-bmi\u3009."},{"issue":"4","key":"10.1016\/j.jinf.2026.106710_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.jinf.2026.106710_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13318-021-00698-w","article-title":"Quantification and explanation of the variability of first-dose amikacin concentrations in critically ill patients admitted to the emergency department: a population pharmacokinetic analysis","volume":"46","author":"De Winter","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jinf.2026.106710_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FTD.0000000000001279","article-title":"Dose optimization of amikacin in the emergency department: a population pharmacokinetics simulation study","volume":"47","author":"Dia","year":"2025","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.jinf.2026.106710_bib24","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1093\/jac\/dkaa158","article-title":"Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach","volume":"75","author":"Perez-Blanco","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2026.106710_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106124","article-title":"Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?","volume":"56","author":"Marsot","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jinf.2026.106710_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ejhpharm-2022-003421","article-title":"Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations","volume":"30","author":"Frost","year":"2023","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"10.1016\/j.jinf.2026.106710_bib28","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","article-title":"An international survey on aminoglycoside practices in critically ill patients: the AMINO III study","volume":"11","author":"Roger","year":"2021","journal-title":"Ann Intensive Care"},{"issue":"1","key":"10.1016\/j.jinf.2026.106710_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41409-022-01851-y","article-title":"Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates","volume":"58","author":"Sava","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.jinf.2026.106710_bib31","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10096-018-3376-6","article-title":"The effect of short-course gentamicin therapy on kidney function in patients with bacteraemia-a retrospective cohort study","volume":"37","author":"Carlsen","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2026.106710_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00228-014-1680-3","article-title":"Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy","volume":"70","author":"Nezic","year":"2014","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:12:55Z","timestamp":1781701975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0163445326000356"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106710","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of amikacin in patients with a haematological disorder: A prospective, observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106710"}}